[Clinical effect of LM-001, prostaglandin synthetic inhibitor, on pain from urinary tract stone and vesical urgency after operation of the bladder or prostate].
Clinical effect of LM-001, a prostaglandin synthetic inhibitor developed from a drug delivery system, was evaluated in 54 patients with pain from urinary tract stones (stone pain) and 32 with vesical urgency after an operation on bladder or prostate. LM-001, felbinac ethyl incorporated in lipid microsphere, wes intravenously administered at the onset of stone pain or vesical urgency. Of 54 with stones and 32 with urgency, 53 and 29 were eligible for response, respectively. The symptoms improved or disappeared in some cases just after the administration and in the majority of patients within 15 minutes, in 49 of 53 patients with stone pain. Further, the effectiveness lasted over 24 hours in 26 of the 49 responding to this agent. On one hand, improvement or disappearance of vesical urgency was recognized in 25 of 29 patients, and the effectiveness was observed shortly after injection in 16 and lasted over 24 hours in 13 cases. Toxicities of this drug were investigated in 54 patients with stone pain and 32 with urinary urgency. Side effects consisted of pain at the injection site in 4, a slight fall of blood pressure in 1, slight visual disturbance in 1, body heat sensation in 1, leukocytosis in 3 and elevation of alkaline phosphatase in 1. These symptoms were transient and disappeared without use of any agent. LM-001 is concluded to be a useful drug for controlling stone pain and vesical urgency since an immediate effect, long durability and high response rates were obtained without severe side
Nakano
E
E
Department of Urology, Osaka University Hospital.
Yoshioka
T
T
Matsuda
M
M
Sonoda
T
T
Yano
H
H
Ihara
Y
Y
Kuroda
H
H
Kishimoto
T
T
Sakurai
T
T
Uchida
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D004337:Drug Carriers; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010648:Phenylacetates / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy*; D011448:Prostaglandin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D011467:Prostate / Q000601:surgery*; D001743:Urinary Bladder / Q000601:surgery*; D014545:Urinary Calculi / Q000503:physiopathology*; D014555:Urination Disorders / Q000188:drug therapy*
D000700:Analgesics; D001713:Biphenyl Compounds; D004337:Drug Carriers; D010648:Phenylacetates; D011448:Prostaglandin Antagonists; C048480:4-biphenylylacetic acid ethyl ester